ArticleJournal of virology2025
Midnolin inhibits coronavirus proliferation by degrading viral proteins.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma extracellular vesicle proteomic analysis identifies WARS as a potential biomarker of infectious mononucleosis.BMC infectious diseases · 2026Article
- The glycosylation variant at residue 381 of the spike protein contributes to virulence shifts in porcine epidemic diarrhea virus during both natural field transmission and laboratory cell passaging with poor cross-protection.Journal of virology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cells utilize proteasomes and selective autophagy to degrade ubiquitin-labeled viral proteins and inhibit viral proliferation. Midnolin, a midbrain nucleolar protein, is reported to use ubiquitin-independent proteasomal degradation to degrade various nuclear proteins including transcription factors encoded by the immediate-early genes. However, it remains unclear whether midnolin can degrade viral protein to hinder viral replication. In this study, midnolin degraded porcine epidemic diarrhea virus (PEDV) S1/S2/M/E proteins to suppress PEDV proliferation. Midnolin has two essential structural domains: the Catch domain and the ubiquitin-like domain. We found that the Catch domain and the ubiquitin-like domain of midnolin concerted to target and degrade PEDV S1/S2/M/E proteins by both the proteasome and selective autophagy. Furthermore, this study indicated that the individual Catch domain of midnolin degraded PEDV S1/S2/M/E proteins through the autophagy pathway, which recruited the E3 ubiquitinating enzyme MARCH8 to ubiquitinate S1/S2/M/E proteins, and that the ubiquitinated proteins were recognized by Tollip and transported to the lysosome for degradation. Collectively, midnolin degraded viral proteins not only through the proteasomal pathway but also revealed a new mechanism of midnolin-mediated virus restriction, where the Catch domain degraded viral proteins using the midnolin (Catch)-MARCH8-Tollip-autophagosome pathway.IMPORTANCEProteasomes and selective autophagy are two ways that inhibit viral proliferation in cells. Midnolin can degrade nuclear proteins. However, whether midnolin can degrade viral protein is unknown. In this study, we found that midnolin degraded porcine epidemic diarrhea virus (PEDV) S1/S2/M/E proteins to suppress PEDV proliferation. During the degradation, two domains of midnolin exerted a vital role. The Catch domain and the ubiquitin-like domain concerted to interact and degrade PEDV S1/S2/M/E proteins through the proteasome pathway. In addition, the individual Catch domain of midnolin degraded PEDV S1/S2/M/E proteins through the autophagy pathway using the midnolin (Catch)-MARCH8-Tollip-autophagosome pathway. Overall, we have discovered a new mechanism of midnolin which acts as a host factor for antiviral function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.